Central India Chronicle

Oral Mucositis Market Size is expected to grow at a CAGR of 6.6% for the study period of 2018-30 by DelveInsight

 Breaking News
  • No posts were found

Oral Mucositis Market Size is expected to grow at a CAGR of 6.6% for the study period of 2018-30 by DelveInsight

September 09
12:36 2021
Oral Mucositis Market Size is expected to grow at a CAGR of 6.6% for the study period of 2018-30 by DelveInsight
Oral Mucositis Market

DelveInsight’s “Oral Mucositis Market Insights, Epidemiology and Market Forecast – 2030” report provides an overview of the disease and market size of Oral Mucositis for the 7MM major pharmaceutical markets, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This report covers the various treatment practices, and Oral Mucositis forecasted epidemiology from 2020 to 2030, segmented by the 7 major markets.

 

Some of the key facts of the Oral Mucositis Market Report:

  1. Increase in OM market size is anticipated for the study period, 2018–2030 with a CAGR of 6.6%.
  2. As per the research study of Seiler et al. (2014), in the breast cancer patients approximately 56% of the patients developed OM of any grade, 48% patients experience mild to moderate grade 1–2 OM, and 8% grade 3–4 OM according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale version 3.0.
  3. In the year 2020, the total incident cases of Oral Mucositis were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018–2030.
  4. As per the DelveInsight estimates, in the United States, the total Grade-specific incident cases of Oral Mucositis were 156,729, 136,107, 209,660, and 94,175 for Grade I, Grade II, Grade III, and Grade IV respectively in the year 2020. These cases are expected to grow in the study period 2018–2030.
  5. As per the research study of Sonis et al., the frequency of oral mucositis is about 30% to 40% in the general cancer patient population.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market

 

Key benefits of the Oral Mucositis Market Report:

  • Oral Mucositis market report covers a descriptive overview and comprehensive insight of the Oral Mucositis epidemiology and Oral Mucositis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  • Oral Mucositis market report provides insights on the current and emerging therapies. 
  • Oral Mucositis market report offers a global historical and forecasted market covering drug outreach in 7 MM.
  • Oral Mucositis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market

 

“According to Delveinsight, females appear to be more likely than males to develop Oral mucositis.”

 

Oral Mucositis (OM) is the most common, debilitating complication of cancer chemotherapy and radiotherapy. It is characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment. The symptoms appear after five to ten days after the chemotherapy treatment or 14 days after the start of radiotherapy. The early symptoms include erythema and light discoloration of the mucosa. As OM progresses, erosive lesions and ulcers are developed.

Mouth sores are extremely painful and are typically the most distressing manifestation. It has significant negative impact on patient’s quality of life (QOL). Potential complications of OM include pain, increased risk of local and systemic infections, bleeding, insufficient food intake, and delays in administration of radiotherapy and/or chemotherapy, dose reduction of the chemotherapy drugs, increased length of hospital stays, associated economic burdens and in some cases life-threatening infections (septicemia in neutropenic cases).

 

“As per DelveInsight insights, the incidence of Grade I and II OM has been observed to be higher in comparison to Grade III-IV cases across all the major markets”

 

Some of the Oral Mucositis Companies are:

  • Amgen/ Swedish Orphan Biovitrum
  • Access Pharmaceuticals
  • Chemo Mouthpiece/ Aurora BioScience
  • Camurus
  • Innovation Pharmaceuticals
  • Enzychem Lifesciences Corporation
  • BrainCool
  • NeoMedLight
  • Monopar Therapeutics
  • MuReva (Lumitex)
  • EpicentRx/Prothex Pharma
  • Soligenix
  • And Many Others.

 

The launch of the emerging therapies is expected to significantly impact the Oral Mucositis treatment scenario in the upcoming years:-

Oral Mucositis Drugs Covered:

  • Kepivance (Palifermin)
  • MuGard
  • Chemo Mouthpiece
  • Episil
  • Brilacidin
  • EC-18
  • Cooral System
  • CareMin650
  • Validive (Clonidine Lauriad)
  • MuReva Phototherapy System
  • RRx-001
  • SGX942
  • And Many Others.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Oral Mucositis

3. SWOT Analysis of Oral Mucositis

4. Oral Mucositis: Market Share (%) Distribution Overview at a Glance: By Country

5. Epidemiology and Market Methodology

6. Oral Mucositis: Disease Background and Overview

7. Diagnosis of Oral Mucositis

8. Epidemiology and Patient Population

9. Epidemiology Scenario: 7MM

10. The United States Epidemiology

11. EU-5 Epidemiology

12. Current Treatment Practices: Oral Mucositis

13. Prevention of Oral Mucositis

14. Guidelines of Oral Mucositis

15. Unmet Needs

16. Patient Journey of Oral Mucositis

17. Key Endpoints in Oral Mucositis Clinical Trials

18. Marketed Therapies

19. Emerging Therapies

20. Oral Mucositis: Seven Major Market Analysis

21. 7MM Market Size

22. The United States Market Size

23. EU-5 Market Size

24. Market Access and Reimbursement of Oral Mucositis Therapies

25. Market Drivers of Oral Mucositis

26. Market Barriers of Oral Mucositis

27. Appendix

28. DelveInsight Capabilities

29. Disclaimer

30. About DelveInsight 

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/oral-mucositis-om-market